Preemptive and Postoperative Intra-articualr Injection of Levobupivacaine and Tramadol
Comparative Study Between Preemptive and Postoperative Intra-articualr Injection of Levobupivacaine and Tramadol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain Shams University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient physical status according to American Society of Anesthesiology (ASA) classes I-II
- Patients free of general diseases prohibiting the use of local anesthesia.
Exclusion Criteria:
- Patients had allergy for local anesthetics or to tramadol
- Patients have psychological or neurological disorders inducing difficulty for evaluation of pain scoring.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Levobupivacaine and tramadol Preemptive
20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.
|
Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
Other Names:
|
|
Active Comparator: Tramadol and levobupivacaine postoperative
20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.
|
Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
Other Names:
|
|
Active Comparator: Tramadol and levobupivacaine preemptive and postoperative
20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.
|
Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
Other Names:
|
|
Active Comparator: Levobupivacaine
20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.
|
Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain control
Time Frame: Pain assessment for 12 hours postoperative
|
Pain sensation after arthroscopy assessed by numeric rating scale depending upon patient facial appearance with severe patient expressing high score and no pain with lowest score
|
Pain assessment for 12 hours postoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ASUH7923/16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.